Polygenic Risk Scoring for Coronary Artery Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this study is to assess the benefit to physicians and patients of adding an integrated risk score (IRS) to existing coronary artery risk tools by conducting a randomized prospective study. IRS combines both an individual's coronary artery disease (CAD) polygenic risk score (PRS) and clinical risk factors, like cholesterol levels and age. This study will examine to what extent IRS knowledge impacts physician/provider behavior as well as clinical outcomes including cholesterol levels and incident heart disease.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes people who are currently treated with lipid-lowering therapy like statins. This suggests that if you are on such medications, you may not be eligible to participate.
Is polygenic risk scoring for coronary artery disease safe for humans?
How does polygenic risk scoring differ from other treatments for coronary artery disease?
Polygenic risk scoring is unique because it uses genetic information to predict an individual's risk of developing coronary artery disease, helping to identify those who might benefit most from preventive treatments. Unlike traditional treatments that focus on managing symptoms or risk factors, this approach aims to enhance risk prediction and personalize prevention strategies.12356
What data supports the effectiveness of the treatment Integrated Risk Score (IRS) for coronary artery disease?
Are You a Good Fit for This Trial?
This trial is for individuals with a moderate risk of heart disease in the next 10 years, who have been previously genotyped for research and are receiving care at a participating institution. It's not open to those who've already had a heart-related event like a heart attack or stroke.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants receive their integrated risk score result for coronary artery disease or standard of care ASCVD Pooled Cohorts Equation
Follow-up
Participants are monitored for clinical outcomes and understanding of CAD risk over time
Deferred Disclosure
Control group receives their integrated risk score result approximately 3 years after enrollment
What Are the Treatments Tested in This Trial?
Interventions
- Integrated Risk Score (IRS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
MyOme
Lead Sponsor
University of Pennsylvania
Collaborator